Coverage on Yahoo! News (May 2025)
Understanding Projects and Companies Through Public Materials.
This page organizes publicly available materials and reference links on company information, research, business activities, joint research, Web3 projects, and overseas expansion related to Fumihisa Kojima.
Biozipcode Inc., Biozipcode™, 5-ALA, GDT, and overseas expansion in Palau and the UAEThe related information is spread across multiple pages and materials.
This page separates pages that provide an overall overview from PDFs and external links that provide more detailed information.
About the Materials Listed Here
The materials listed on this page include official websites, affiliated company pages, university announcements, papers, patent information, business introductions, explanatory materials, links, and PDFs.
Some materials may include R&D-stage content, conceptual business plans, past plans, or projects under consideration. Please read the materials as explanations or reference information as of the time they were prepared.
For information related to medical, investment, and overseas corporate matters, please also review the separate Medical, Investment & Other Disclaimers page.
Main Pages on the Official Fumihisa Kojima Website (Business & Project Explanations)
| Businesses & Projects | Content |
|---|---|
| Biozipcode™ & Diabetes Cure | Organizes research aimed at curing diabetes, Biozipcode™, and 5-ALA. |
| Web3 Projects | Organizes the relationship between Biozipcode Group, medical research, and Web3. |
| AI & Computational Science Business | Organizes the technical background, including bioinformatics and in silico analysis. |
| Overseas Expansion Business | Organizes Palau, the UAE, the GCC, regional development, and overseas business expansion. |
| Global Medical Expansion | Organizes pre-disease (me-byo), diabetes, Biozipcode™, and medical tourism concepts. |
Public Materials & Reference Links.
Some links and PDF materials are provided after a nondisclosure agreement has been signed with the relevant affiliated company, or in response to individual inquiries.
Basic Information on Fumihisa Kojima
These pages provide information on Fumihisa Kojima’s profile, career history, roles, affiliated companies, and technology journey.
They organize his activities by field, from web production, system development, bioinformatics, GPGPU, blockchain, AML/compliance, medical and biotech, and overseas expansion.
Overall Businesses & Projects
This page provides an overview of the major projects involving Fumihisa Kojima.
It organizes multiple business areas by field, including medical and biotech, Web3, AI and computational science, overseas expansion, and global medical expansion.
Materials Related to Studio Makyu Co., Ltd.
Studio Makyu Co., Ltd. is a company where Fumihisa Kojima serves as Representative Director.
Web production, DTP design, system development, web marketing, SEO, GPGPU, blockchain-related business, and bioinformatics support are among its activities.
It has also become the foundation of today’s Biozipcode Inc. and AI/computational science-related businesses.
Materials Related to Overseas Expansion, Global Medical Development, and Palau
The overseas expansion involving Fumihisa Kojima connects the UAE/GCC, Palau, and Japan, while advancing business concepts that combine medicine, pre-disease (me-byo), 5-ALA, Biozipcode™, Web3, tourism, and regional development.
In the UAE and GCC region, with Dubai as a key base, the project is considering medical tourism, a treatment center aiming to cure diabetes, advanced precision pre-disease (me-byo) health screening, 24/7/365 monitoring services, 5-ALA, longevity, and a Web3-enabled medical service platform.
In Palau, meanwhile, concepts combining blockchain, digital payments, tourism, healthcare, SDGs, and regional development have been under consideration. Palau has beautiful nature, marine resources, and tourism assets, while also facing challenges in lodging, housing, waste treatment, agriculture, food self-sufficiency, education, medical workforce development, diabetes, and lifestyle-related diseases.
Materials Related to Biozipcode Inc. and Biozipcode™ Technology
Biozipcode Inc. is a medical and biotech company where Fumihisa Kojima serves as Representative Director.
The company is advancing applied research centered on cell-targeting technology Biozipcode™, including applications in diabetes, cancer, autoimmune diseases, intractable diseases, diagnostics, and drug delivery.
Biozipcode™ is a technology aimed at identifying specific cells and tissues and delivering drugs or diagnostic substances to the intended location. It is positioned not only for diabetes research but also as a platform technology with multiple application areas, including cancer therapy, biomarkers, drug discovery support, and cell-targeted therapies.
*This page is not intended to solicit investments; therefore, the business plan cannot be disclosed on this page.
Materials Related to Diabetes Cure Research, 5-ALA, and Social Implementation
Research aiming to cure diabetes is one of the main themes advanced by Biozipcode Inc..
This research does not view diabetes merely as a blood-glucose issue; instead, it focuses on abnormal cellular states that remain in the body, bone marrow-derived cells, diabetes stem cells, and mechanisms that inhibit regeneration.
In 2023, research findings on diabetic mice by a research team led by Prof. Hideto Kojima were published in Communications Biology, a Nature Portfolio journal. This study is one of the important scientific backgrounds for research aiming at a fundamental treatment for diabetes.
At present, this is not an approved treatment for humans, and it is necessary to proceed step by step with clinical research, biomarkers, 5-ALA, collaboration with medical institutions, and social implementation. Meanwhile, a certain amount of human research has been conducted on 5-ALA, and its applications are being advanced.
5-ALA is a substance that also exists in the body and is known to be related to mitochondria and energy metabolism. 5-ALA is treated as one of the important themes related to diabetes, pre-disease (me-byo), metabolism, medical tourism, and global medical expansion.
*This page is not intended to solicit investments; therefore, the business plan cannot be disclosed on this page.
Important Notes.
The materials and links listed on this page are provided for informational purposes. They consist of information related to Fumihisa Kojima’s activities, affiliated companies, research and development, and related projects, and are not intended to solicit or invite investments, deposits, loans, investment funds, or similar contributions from the general public.
Content related to medical research, 5-ALA, Biozipcode™, research aiming to cure diabetes, pre-disease (me-byo), GDT, PWD / PWDT, and overseas medical expansion does not guarantee any specific therapeutic effect, safety, investment return, value, regulatory approval, or clinical trial result.
For decisions related to diabetes or any other disease, please be sure to consult a physician or other medical professional. In addition, investment, tax, legal, and accounting decisions should be confirmed with specialists in the relevant fields.